Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

The application of custom CD34+ hematopoietic stem cell (HSC) engrafted humanized models is a core component of evaluating immuno-oncology (I/O) therapeutics. These specialized in vivo platforms generate a multi-lineage human immune system, providing the necessary context for assessing human-specific modalities like CAR-T, CAR-NK, and TCR-T cell therapies. The process involves tailored engraftment protocols, rigorous quality control of immune reconstitution, and study designs aligned with IND and IMPD submission requirements.

The Challenge of Modeling Human Immunology for Cell Therapies

Evaluating the in vivo activity of somatic cell therapies requires a test system that recapitulates the human immune environment. A standard, one-size-fits-all preclinical testing template does not exist for these complex modalities. The biological activity of a CAR-T or TCR-T therapy is dependent on interactions that cannot be modeled in conventional in vivo systems.

A tailored, data-driven preclinical strategy is a prerequisite for a successful regulatory submission. This involves creating specialized models where human tumor xenografts can be challenged by a co-existing and functional human immune system.

A Tailored Approach to CD34+ Model Development

Our scientific team develops custom humanized models by engrafting immunodeficient host systems with CD34+ HSCs. This process is meticulously controlled to promote robust, multi-lineage reconstitution of the human immune system.

• Strain Selection: We advise on the appropriate immunodeficient background strain (e.g., NSG, NOG) based on the specific requirements of the therapeutic and tumor model.

• Engraftment & Monitoring: Following irradiation and HSC injection, animals are monitored for health and immune reconstitution. Peripheral blood is periodically sampled and analyzed by flow cytometry to quantify the presence of human immune cell subsets.

• Functional Validation: Models are only released for efficacy studies after meeting stringent, pre-defined criteria for human immune cell engraftment levels, ensuring data integrity and study reproducibility.

This disciplined approach provides a reliable platform for generating the pharmacology and efficacy data required for regulatory filings with agencies like the FDA and MHRA.

Translational Validation and Regulatory Alignment

The principal value of humanized models is their ability to validate therapies that depend on human-specific biological interactions. This platform provides a controlled in vivo environment to generate predictive data, minimizing clinical risk regardless of the therapeutic modality.

While our focus here is immuno-oncology, the utility of this approach has been demonstrated in other complex fields. For instance, published work shows that in vivo platforms using human cells can effectively predict therapeutic responses to genetic interventions, such as AAV-based gene therapy for metabolic disorders (PMID: 20976059, 26081744). The strategic insight is consistent: by validating a human-specific mechanism in a properly humanized model, sponsors gain confidence and can assemble a more robust data package for IND or IMPD submissions.

All studies are conducted within our >100,000 sq ft facility, which includes GxP-compliant environments and full histology services to support primary and secondary endpoint analysis.

Animal Welfare

All animal studies are conducted in strict compliance with USDA regulations. We are committed to the highest standards of animal care and welfare.

• 3Rs Principle: Our study designs and institutional policies adhere to the principles of Replacement, Reduction, and Refinement.

• Enrichment: We provide enhanced housing conditions with cognitive and social enrichment programs during the in-life phase of all studies.

• Oversight: All protocols are reviewed and approved by our Institutional Animal Care and Use Committee (IACUC).